Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25525597 | 0.78 | DRD2 (0.33) | DRD2ALDH1A1KDM4EHTT | |
| SCHEMBL11817461 | 0.78 | HTT (0.34) | DRD2HTT | |
| SCHEMBL12942820 | 0.78 | HTT (0.34) | DRD2HTT | |
| SCHEMBL25149793 | 0.78 | DPP4 (0.36) | DRD2KDM4EHTT | |
| SCHEMBL25568564 | 0.76 | KMT2A (0.40) | ALDH1A1GAA | |
| SCHEMBL7991761 | 0.76 | — | — | |
| SCHEMBL24767282 | 0.75 | CTSS (0.36) | POLBKDM4E | |
| SCHEMBL6845293 | 0.74 | FFAR3 (0.54) | POLBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL11573005 | 0.74 | FFAR3 (0.54) | POLBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL4761467 | 0.73 | EPHX1 (0.37) | DRD2ALDH1A1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | POLB 2413/4885DRD2 3676/4885ALDH1A1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.